Bistratal conjunctival microneedle for long-acting dual treatment of dry eye disease via efficient ocular drug delivery
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Ocular Surface and Contact Lens · Advanced Drug Delivery Systems · Corneal Surgery and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (54)
Show source-provided references
1. TFOS DEWS III
2. TFOS DEWS II epidemiology report10.1016/j.jtos.2017.05.003 ↗
3. TFOS DEWS III: diagnostic methodology10.1016/j.ajo.2025.05.033 ↗
4. Dry eye10.1056/NEJMra1407936 ↗
5. TFOS DEWS III: executive summary
6. TFOS DEWS III: management and therapy10.1016/j.ajo.2025.05.039 ↗
7. Progress in drug formulation design and delivery of medicinal substances used in ophthalmology10.1016/j.ijpharm.2021.121012 ↗
8. Challenges and strategies for the delivery of biologics to the cornea10.1016/j.jconrel.2021.04.008 ↗
9. Drug delivery strategies to improve the treatment of corneal disorders10.1016/j.heliyon.2025.e41881 ↗
10. Corneal-PAMPA: a novel, non-cell-based assay for prediction of corneal drug permeability10.1016/j.ejps.2018.12.012 ↗
11. The most common barriers to Glaucoma medication adherence: a cross-sectional survey10.1016/j.ophtha.2015.03.026 ↗
12. A novel eye drop application monitor to assess patient compliance with a prescribed regimen: a pilot study10.1038/eye.2015.155 ↗
13. Microneedles for drug and vaccine delivery10.1016/j.addr.2012.04.005 ↗
14. Progress in the application of Microneedles in eye disorders and the proposal of the upgraded Microneedle with Spinule10.1007/s11095-024-03658-6 ↗
15. Microneedles for advanced ocular drug delivery10.1016/j.addr.2023.115082 ↗
16. Hollow microneedles for ocular drug delivery10.1016/j.jconrel.2024.05.013 ↗
17. Dissolving microneedles: applications and growing therapeutic potential10.1016/j.jconrel.2022.05.045 ↗
18. Polymer-based microneedle composites for enhanced non-transdermal drug delivery
19. Single administration of a biodegradable, separable microneedle can substitute for repeated application of eyedrops in the treatment of infectious keratitis
20. Self-implantable double-layered micro-drug-reservoirs for efficient and controlled ocular drug delivery10.1038/s41467-018-06981-w ↗
21. Biodegradable silicon nanoneedles for ocular drug delivery10.1126/sciadv.abn1772 ↗
22. A rapid corneal healing microneedle for efficient ocular drug delivery10.1002/smll.202104657 ↗
23. Self-implantable core-shell microneedle patch for long-acting treatment of keratitis via programmed drug release10.1002/smll.202310461 ↗
24. Customized corneal cross-linking with Microneedle-mediated riboflavin delivery for keratoconus treatment
25. A transformative wearable corneal microneedle patch for efficient therapy of ocular injury and infection
26. Highly efficient intrastromal dual-drug delivery by a dissolving bilayer microneedle for synergistic therapy against corneal neovascularization10.1021/acsnano.5c10610 ↗
27. Human corneal lenticules decorated with mesenchymal-stem-cells-encapsulated microneedles for cornea stroma regeneration10.1021/acsnano.5c04606 ↗
29. Roles of the conjunctiva in ocular drug delivery: a review of conjunctival transport mechanisms and their regulation10.1016/j.ejpb.2004.12.007 ↗
30. Phenylboronic acid-tethered chondroitin sulfate-based mucoadhesive nanostructured lipid carriers for the treatment of dry eye syndrome10.1016/j.actbio.2019.08.035 ↗
31. Tacrolimus loaded cationic liposomes for dry eye treatment
32. Benzalkonium chloride-induced dry eye disease animal models: current understanding and potential for translational research10.4103/IJO.IJO_2791_22 ↗
33. The Draize eye test10.1016/S0039-6257(01)00211-9 ↗
34. Novel hydroxypropyl-guar gellable lubricant eye drops for treatment of dry eye10.1007/s12325-010-0052-3 ↗
35. The effect of topical pranoprofen 0.1% on the clinical evaluation and conjunctival HLA-DR expression in dry eyes10.1097/ICO.0b013e31824988e5 ↗
36. Clinical efficacy of 0.1% pranoprofen in treatment of dry eye patients: a multicenter, randomized, controlled clinical trial10.3760/cma.j.issn.0366-6999.20140048 ↗
37. Tear flow in cyclosporine recipients10.1016/S0161-6420(95)31071-8 ↗
38. Evaluation of the schirmer and phenol red thread tests for measuring tear secretion in rabbits10.1136/vr.156.15.485 ↗
39. TFOS DEWS II pathophysiology report10.1016/j.jtos.2017.05.011 ↗
40. The efficacy of an irrigating eyelid retractor-facilitated ocular rinse on MMP-9 expression and dry eye disease10.1016/j.aopr.2024.05.002 ↗
41. Interventions for dry eye: an overview of systematic reviews10.1001/jamaophthalmol.2023.5751 ↗
42. Comparison of therapeutic effects of 0.05% cyclosporine A versus 0.1% fluorometholone in Chinese patients with mild dry eye unresponsive to artificial tears: a randomized control study10.1186/s12886-024-03771-5 ↗
43. Lifitegrast for the treatment of dry eye disease: results of a phase III, randomized, double-masked, placebo-controlled trial (OPUS-3)10.1016/j.ophtha.2016.09.025 ↗
44. A temperature-sensitive gel of pranoprofen with stable tear film, anti-inflammatory, and sustained-release effects for alleviating dry eye symptoms
45. Sodium hyaluronate and pranoprofen improve visual function and reduce inflammation in patients with dry eye10.1080/08923973.2024.2390449 ↗
46. Aids for eye drop administration10.1016/j.survophthal.2016.12.009 ↗
47. A systematic review of improper eye drop application and role of pharmacists for patient education10.1080/08164622.2025.2457431 ↗
48. Pharmacokinetic differences between ocular inserts and eyedrops10.1089/jop.1996.12.5 ↗
49. One-side-coated insert as a unique ophthalmic drug delivery system10.1016/S0168-3659(03)00362-6 ↗
50. Development and in vitro-in vivo evaluation of ocular insert containing ketorolac tromethamine and moxifloxacin hydrochloride10.1016/j.pharma.2024.10.002 ↗
51. Efficacy of hydroxypropyl cellulose ophthalmic inserts (LACRISERT) in subsets of patients with dry eye syndrome: findings from a patient registry10.1097/ICO.0b013e3181e3f05b ↗
52. Topical drug delivery devices: a review10.1016/j.exer.2018.01.010 ↗
53. Dose-dependent benzalkonium chloride toxicity imparts ocular surface epithelial changes with features of dry eye disease10.1016/j.jtos.2019.11.006 ↗
54. In vivo efficacy of imatinib mesylate, a tyrosine kinase inhibitor, in the treatment of chemically induced dry eye in animal models10.1167/tvst.10.11.14 ↗